- Home
- HTFL vs DNTH Comparison
HTFL vs DNTH Comparison
Compare HTFL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTFL | DNTH |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HTFL | DNTH |
|---|---|---|
| Price | $26.91 | $79.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $38.20 | ★ $123.09 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 03-18-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $23.03 | $30.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.13 | $13.37 |
| 52 Week High | $41.22 | $88.45 |
Technical Indicators
Market Signals| Indicator | HTFL | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 67.73 |
| Support Level | $25.56 | $34.83 |
| Resistance Level | $32.52 | $88.45 |
| Average True Range (ATR) | 1.79 | 5.09 |
| MACD | 0.74 | 0.09 |
| Stochastic Oscillator | 79.04 | 68.99 |
Price Performance
Historical ComparisonAbout HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.